{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:02:20Z","timestamp":1785927740624,"version":"3.56.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":394,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Despite receiving guideline-directed medical heart failure (HF) therapy, patients with pulmonary hypertension associated with left heart disease (PH-LHD) experience higher mortality and hospitalization rates than the general HF population. AZD3427 is a functionally selective, long-acting mimetic of relaxin, a hormone that has the potential to induce vasodilation and prevent fibrosis. In a phase 1b study conducted in patients with HF, AZD3427 demonstrated a favourable safety and pharmacokinetic profile. To address the unmet medical need in patients with PH-LHD in the context of HF, AZD3427 is currently under development as a potential treatment option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>The Re-PHIRE study is a phase 2b, randomized, double-blind, placebo-controlled, multicentre, dose-ranging study to evaluate the effect of AZD3427 on a broad range of PH-LHD phenotypes. In total, 220 patients will be randomized to four treatment groups to receive a subcutaneous injection of AZD3427 or placebo every 2 weeks for 24 weeks. The primary endpoint of the study is the change in pulmonary vascular resistance in patients treated with AZD3427 versus placebo after 24 weeks of treatment. Key secondary endpoints include changes in mean pulmonary arterial pressure, pulmonary artery wedge pressure, systemic vascular resistance, 6-min walking distance, N-terminal pro B-type natriuretic peptide levels, echocardiographic parameters, and health-related quality of life (assessed by the Kansas City Cardiomyopathy Questionnaire).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Re-PHIRE is the first study of a relaxin mimetic in patients with PH-LHD. The insights gained from the Re-PHIRE study are expected to inform the further development of AZD3427 in the PH-LHD population, including identifying the most suitable pulmonary hypertension and HF phenotypes for treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15203","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:34:08Z","timestamp":1737347648000},"page":"1956-1964","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Relaxin Mimetic in Pulmonary Hypertension Associated with Left Heart Disease: Design and Rationale of Re-PHIRE"],"prefix":"10.1093","volume":"12","author":[{"given":"Marcin","family":"Ufnal","sequence":"first","affiliation":[{"name":"Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Connolly","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Millegard","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Surkova","sequence":"additional","affiliation":[{"name":"Early Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca , Cambridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Guazzi","sequence":"additional","affiliation":[{"name":"University of Milan School of Medicine, San Paolo University Hospital , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Bonderman","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ezekowitz","sequence":"additional","affiliation":[{"name":"Canadian VIGOUR Centre, University of Alberta , Edmonton ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"The Heart Center, Copenhagen University Hospital, Rigshospitalet , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Ciurzy\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology with the Centre for Management of Venous Thromboembolic Disease, Medical University of Warsaw , Warsaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel L\u00f3pez","family":"Vilella","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplantation Unit, La Fe University and Polytechnic Hospital , Valencia ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Heart Failure Program, Yale School of Medicine , New Haven, Connecticut ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Gardner","sequence":"additional","affiliation":[{"name":"Scottish National Advanced Heart Failure Service, Golden Jubilee National Hospital , Clydebank ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Jansa","sequence":"additional","affiliation":[{"name":"2nd Department of Medicine, Charles University and General University Hospital , Prague ,","place":["Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"van Wijk","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Zuyderland Medical Center , Heerlen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama , Toyama ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Bj\u00f6rklund","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Uppsala University Hospital , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Cheng","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Rosenkranz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Intensive Care Medicine, Center for Molecular Medicine Cologne (CMMC), Cologne Cardiovascular Research Center (CCRC), Medical Faculty, University of Cologne , Cologne ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"2026021804271491500_ehf215203-bib-0001","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021804271491500_ehf215203-bib-0002","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jacc.2020.06.069","article-title":"Pulmonary hypertension in HFpEF and HFrEF: JACC review topic of the week","volume":"76","author":"Guazzi","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2026021804271491500_ehf215203-bib-0003","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/s0735-1097(00)01102-5","article-title":"Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure","volume":"37","author":"Ghio","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2026021804271491500_ehf215203-bib-0004","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.jacc.2008.11.051","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study","volume":"53","author":"Lam","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026021804271491500_ehf215203-bib-0005","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jchf.2013.05.001","article-title":"Clinical features, hemodynamics, and outcomes of pulmonary hypertension due to chronic heart failure with reduced ejection fraction: pulmonary hypertension and heart failure","volume":"1","author":"Miller","year":"2013","journal-title":"JACC Heart Fail."},{"key":"2026021804271491500_ehf215203-bib-0006","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1093\/eurheartj\/ehv512","article-title":"Left ventricular heart failure and pulmonary hypertension","volume":"37","author":"Rosenkranz","year":"2016","journal-title":"Eur Heart J"},{"key":"2026021804271491500_ehf215203-bib-0007","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jchf.2014.07.010","article-title":"The diastolic pulmonary gradient does not predict survival in patients with pulmonary hypertension due to left heart disease","volume":"3","author":"Tampakakis","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2026021804271491500_ehf215203-bib-0008","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/ejhf.1943","article-title":"Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European monitoring study for heart failure (MEMS-HF)","volume":"22","author":"Angermann","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026021804271491500_ehf215203-bib-0009","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/j.jacc.2017.08.010","article-title":"Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction","volume":"70","author":"Givertz","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026021804271491500_ehf215203-bib-0010","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.jjcc.2015.07.015","article-title":"Pulmonary hypertension due to left heart disease: the prognostic implications of diastolic pulmonary vascular pressure gradient","volume":"67","author":"Ibe","year":"2016","journal-title":"J Cardiol"},{"key":"2026021804271491500_ehf215203-bib-0011","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/S2213-2600(20)30317-9","article-title":"Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study","volume":"8","author":"Maron","year":"2020","journal-title":"Lancet Respir Med"},{"key":"2026021804271491500_ehf215203-bib-0012","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12872-022-02492-1","article-title":"Risk prediction in pulmonary hypertension due to chronic heart failure: incremental prognostic value of pulmonary hemodynamics","volume":"22","author":"Quan","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"2026021804271491500_ehf215203-bib-0013","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamacardio.2018.0128","article-title":"Association between hemodynamic markers of pulmonary hypertension and outcomes in heart failure with preserved ejection fraction","volume":"3","author":"Vanderpool","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2026021804271491500_ehf215203-bib-0014","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2026021804271491500_ehf215203-bib-0015","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"2023","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804271491500_ehf215203-bib-0016","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.jacc.2023.04.057","article-title":"Management of worsening heart failure with reduced ejection fraction: JACC focus seminar 3\/3","volume":"82","author":"Greene","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021804271491500_ehf215203-bib-0017","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1152\/physrev.00001.2012","article-title":"Relaxin family peptides and their receptors","volume":"93","author":"Bathgate","year":"2013","journal-title":"Physiol Rev"},{"key":"2026021804271491500_ehf215203-bib-0018","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1152\/ajpregu.00148.2017","article-title":"Relaxin-mediated renal vasodilation in the rat is associated with falls in glomerular blood pressure","volume":"314","author":"Deng","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2026021804271491500_ehf215203-bib-0019","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.tem.2018.02.008","article-title":"Heart disease and relaxin: new actions for an old hormone","volume":"29","author":"Devarakonda","year":"2018","journal-title":"Trends Endocrinol Metab"},{"key":"2026021804271491500_ehf215203-bib-0020","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1523-1755.2005.00384.x","article-title":"The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway","volume":"68","author":"Heeg","year":"2005","journal-title":"Kidney Int"},{"key":"2026021804271491500_ehf215203-bib-0021","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/bph.13523","article-title":"The actions of relaxin on the human cardiovascular system","volume":"174","author":"Sarwar","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2026021804271491500_ehf215203-bib-0022","doi-asserted-by":"publisher","first-page":"8217","DOI":"10.1096\/fj.201902506R","article-title":"The anti-fibrotic actions of relaxin are mediated through AT(2) R-associated protein phosphatases via RXFP1-AT(2) R functional crosstalk in human cardiac myofibroblasts","volume":"34","author":"Wang","year":"2020","journal-title":"FASEB J"},{"key":"2026021804271491500_ehf215203-bib-0023","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1801291","article-title":"Effects of serelaxin in patients with acute heart failure","volume":"381","author":"Metra","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021804271491500_ehf215203-bib-0024","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/eurheartj\/eht459","article-title":"A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure","volume":"35","author":"Ponikowski","year":"2014","journal-title":"Eur Heart J"},{"key":"2026021804271491500_ehf215203-bib-0025","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1164\/ajrccm.166.1.at1102","article-title":"ATS statement: guidelines for the six-minute walk test","volume":"166","author":"ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021804271491500_ehf215203-bib-0026","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/s0735-1097(00)00531-3","article-title":"Development and evaluation of the Kansas City cardiomyopathy questionnaire: a new health status measure for heart failure","volume":"35","author":"Green","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2026021804271491500_ehf215203-bib-0027","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/CIRCRESAHA.118.313650","article-title":"Medical therapy for heart failure associated with pulmonary hypertension","volume":"124","author":"Zelt","year":"2019","journal-title":"Circ Res"},{"key":"2026021804271491500_ehf215203-bib-0028","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"Eur Heart J"},{"key":"2026021804271491500_ehf215203-bib-0029","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"key":"2026021804271491500_ehf215203-bib-0030","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"2026021804271491500_ehf215203-bib-0031","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijcard.2018.12.078","article-title":"Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension","volume":"283","author":"Kramer","year":"2019","journal-title":"Int J Cardiol"},{"key":"2026021804271491500_ehf215203-bib-0032","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01886-2017","article-title":"Macitentan in pulmonary hypertension due to left ventricular dysfunction","volume":"51","author":"Vachiery","year":"2018","journal-title":"Eur Respir J"},{"key":"2026021804271491500_ehf215203-bib-0033","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/HP.S165092","article-title":"Effects of human relaxin-2 (serelaxin) on hypoxic pulmonary vasoconstriction during acute hypoxia in a sheep model","volume":"6","author":"Schiffner","year":"2018","journal-title":"Hypoxia"},{"key":"2026021804271491500_ehf215203-bib-0034","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3233\/CH-170269","article-title":"Pulmonary arterial compliance and pulmonary hemodynamic effects of serelaxin in a sheep model","volume":"66","author":"Schiffner","year":"2017","journal-title":"Clin Hemorheol Microcirc"},{"key":"2026021804271491500_ehf215203-bib-0035","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.668222","article-title":"Relaxin inhibits ventricular arrhythmia and asystole in rats with pulmonary arterial hypertension","volume":"8","author":"Martin","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026021804271491500_ehf215203-bib-0036","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ejhf.2927","article-title":"Safety, pharmacokinetics, and pharmacodynamics of AZD3427, a functionally selective long acting relaxin mimetic agonist of the RXFP1 receptor. ESC","volume":"24","author":"Ufnal","year":"2023","journal-title":"Heart Fail"},{"key":"2026021804271491500_ehf215203-bib-0037","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1161\/CIRCULATIONAHA.113.001458","article-title":"Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study","volume":"128","author":"Bonderman","year":"2013","journal-title":"Circulation"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1956\/66956256\/eschf_12_3_1956.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/3\/1956\/66956256\/eschf_12_3_1956.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:27:20Z","timestamp":1771406840000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/3\/1956\/8488360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":37,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,1,20]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15203","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"2024-05-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}